These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 26394632

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
    Tonialini L, Bonfichi M, Ferrero S, Malipiero G, Nozza A, Argnani L, Zinzani PL.
    Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy.
    Koenig G, Stevens TM, Peker D.
    Histopathology; 2015 Dec; 67(6):930-2. PubMed ID: 25900626
    [No Abstract] [Full Text] [Related]

  • 26. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.
    Blood; 2018 Nov 15; 132(20):2115-2124. PubMed ID: 30181172
    [Abstract] [Full Text] [Related]

  • 27. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC.
    Br J Haematol; 2019 Jan 15; 184(2):232-241. PubMed ID: 30203839
    [Abstract] [Full Text] [Related]

  • 28. What Is the best treatment for HIV-associated multicentric Castleman disease?
    Bower M, Dalla Pria A.
    Clin Adv Hematol Oncol; 2012 Mar 15; 10(3):207-9. PubMed ID: 22402432
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.
    Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM.
    Clin Cancer Res; 2010 Mar 01; 16(5):1652-61. PubMed ID: 20179212
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease.
    Neuville S, Agbalika F, Rabian C, Brière J, Molina JM.
    Am J Hematol; 2005 Aug 01; 79(4):337-9. PubMed ID: 16044438
    [Abstract] [Full Text] [Related]

  • 36. [Multicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z, Řehák Z, Adamová Z, Koukalová R, Pour L, Krejčí M, Boichuk I, Sandecká V, Krejčí M, Štork M, Ševčíková S, Král Z.
    Vnitr Lek; 2022 Aug 01; 68(1):41-53. PubMed ID: 35459346
    [Abstract] [Full Text] [Related]

  • 37. Siltuximab (CNTO 328): a promising option for human malignancies.
    Chen R, Chen B.
    Drug Des Devel Ther; 2015 Aug 01; 9():3455-8. PubMed ID: 26170629
    [Abstract] [Full Text] [Related]

  • 38. IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report.
    Galeotti C, Tran TA, Franchi-Abella S, Fabre M, Pariente D, Koné-Paut I.
    J Pediatr Hematol Oncol; 2008 Dec 01; 30(12):920-4. PubMed ID: 19131781
    [Abstract] [Full Text] [Related]

  • 39. JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
    Patel M, Ikeda S, Pilat SR, Kurzrock R.
    JAMA Dermatol; 2017 May 01; 153(5):449-452. PubMed ID: 28241173
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.